Calm Water Therapeutics’ Post

🗞 IN THE NEWS: In a clinical trial at NIH’s National Cancer Institute (NCI), researchers tested the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (called ViPOR) in 50 patients with DLBCL, the most common type of lymphoma. The treatment shrank tumors substantially in 26 of 48 (54%) evaluable patients, with 18 (38%) of those patients’ tumors disappearing entirely, known as a complete response. At two years, 36% of all patients were alive and 34% were free of disease. These benefits were seen mainly in people with two specific subtypes of DLBCL. ➡ Read more in this piece by MedPage Today: https://lnkd.in/eK75QQyd Additional outlets that have covered ViPOR include Healio, European Pharmaceutical Review, HealthDay News, Clinical Trials Arena, etc. #CancerResearch #Lymphoma #ClinicalTrial #Health #Medicine

On #WorldLungDay, DISCO Pharmaceuticals GmbH is proud to stand with the global community in raising awareness about lung health and the impact of lung diseases such as #LungCancer.   At DISCO, we are at the forefront of innovation. With our breakthrough cell #surfaceome discovery technology, we have completed the first-ever mapping of #SmallCellLungCancer (SCLC). Leveraging this knowledge, we have launched the development of #SCLC target-specific therapeutics, and we are committed to improving patient care by providing more effective, targeted treatment options.    Learn more about how we are transforming cancer care by expanding the molecular target space using the link in the first comment below.   #WLD #WLD2024 #LungHealth #HealthForAll #HealthyLungsForLife #drugdiscovery #proteomics #optoproteomics  

📌 Current Trend in Pharmaceutical Industry: Personalized medicine is revolutionizing healthcare by customizing treatments to individual patients based on their genetic makeup. As pharmacogenomics advances, pharma professionals are pivotal in developing targeted therapies that enhance outcomes and minimize side effects. The future of this field is filled with promising opportunities! 🏷 Examples of personalized medicine in action: 🔖 Herceptin (Trastuzumab) for HER2-positive breast cancer 🔖 Keytruda (Pembrolizumab) for melanoma and lung cancer 🔖 Kalydeco (Ivacaftor) for cystic fibrosis 🔖 Tamoxifen for breast cancer treatment 🔖 Warfarin for blood thinning Embracing #Pharma, #PersonalizedMedicine, and #Pharmacogenomics is shaping the future of healthcare! 🧬✨

Forbion is thrilled to support portfolio company SynOx Therapeutics as it advances in the fight against Tenosynovial Giant Cell Tumour (TGCT), a rare and debilitating disease. The company announced the completion of an extension to its Series B financing, bringing the total raised to an impressive $92 million. This funding is advancing the TANGENT study, SynOx’s pivotal Phase 3 clinical trial for emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody that has the potential to be best-in-class for TGCT treatment. The TANGENT study has officially dosed its first patients and will be conducted globally across multiple centers. With a rigorous, randomized, double-blind, placebo-controlled design, the trial will evaluate overall response rate, functional and quality of life improvements, tumour volume impact, and response duration in approximately 130 patients. We are inspired by SynOx’s commitment to transforming TGCT treatment and look forward to sharing updates from this promising trial. For more details about TANGENT go to ClinicalTrials.gov identifier: NCT05417789 Click on the following link to learn more: https://lnkd.in/eHANaNMc #Forbion #SynOxTherapeutics #SeriesB #TGCT #Biotech #ClinicalTrials #HealthcareInnovation #lifesciences #biotech Dirk Kersten Audrey Cacaly

FDA approves blood test for Colorectal Cancer Screening July 29, 2024 In 2020, worldwide, more than 1.9 million new cases of CRC were detected and more than 930000 deaths were reported. Gurdant's Shield is the first blood test/ liquid-biopsy. It offers a non-invasive, easy, convenient and pleasant screening option. It avoids the complications and delays of a tissue biopsy. it can be completed during any healthcare visit. It detects cancers by seeking out the DNA that cancerous tumors release into the bloodstream. #coloncancer #diagnostictest #researchanddevelopment #innovation #dnatest #healthcare #lifesciences #biotechnology #pharmaceuticals #liquidbiopsy

Excited to share a new study 📄 by Phil Green (Chesapeake Pharma LLC), Andreas Schneider, and Jakob Lange (Ypsomed AG) on the growing role of large-volume subcutaneous injections in biopharmaceuticals.   The study highlights the ongoing shift from intravenous to subcutaneous delivery, offering more patient-friendly, at-home care options 💙.   Key insights:  💡 15% of intravenous and subcutaneous biopharmaceuticals involve large-volume injections, targeting conditions such as cancer, autoimmune, neurological, and cardiovascular diseases.  💡 For cancer treatments, large-volume subcutaneous injections often require doses of 5.0-20.0 mL every three weeks, while non-cancer injections are typically less than 5.0 mL and self-administered monthly.   The research emphasizes the need for innovative drug delivery systems and formulations to support this evolving landscape. #SelfCare #HealthcareInnovation #SubcutaneousInjections #DrugDelivery #PatientCare

⚡ 𝘼𝙚𝙧𝙤𝙫𝙖𝙩𝙚 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨' 𝙄𝙣𝙝𝙖𝙡𝙚𝙙 𝙂𝙡𝙚𝙚𝙫𝙚𝙘 𝙁𝙖𝙞𝙡𝙨 𝙞𝙣 𝙋𝘼𝙃 𝙎𝙩𝙪𝙙𝙮, 𝙎𝙩𝙤𝙘𝙠 𝙋𝙡𝙪𝙢𝙢𝙚𝙩𝙨 🌐 𝗜𝗻 𝗝𝘂𝗻𝗲 𝟮𝟬𝟮𝟰, Aerovate Therapeutics, Inc.’ attempt to repurpose Novartis' cancer drug Gleevec as an inhaled #treatment for #pulmonaryarterialhypertension (PAH) has failed. Following the drug's failure to meet its goals in a phase 2b study, Aerovate's stock dropped ⬇️ by a staggering 93.3% on Monday. The IMPACHT study evaluated three doses of a dry powder inhaled version of imatinib in PAH patients. Although the #drug was well tolerated, it did not show any improvement in pulmonary vascular resistance when compared to a placebo, Aerovate stated in a press release. The study results were disappointing across the board. The drug did not achieve "meaningful improvements" in the secondary endpoint of change in six-minute walk distance and failed to meet "several" other secondary endpoints. 𝙇𝙤𝙤𝙠 𝙖𝙩 𝙤𝙪𝙧 𝘾𝙤𝙧𝙧𝙚𝙡𝙖𝙩𝙚𝙙 𝙍𝙚𝙥𝙤𝙧𝙩 👉: https://bit.ly/4cg4JXJ #PAH #stock #Placebo #CancerDrug #prophecymarketinsights

Day 3 at the Festival of Biologics in Basel, and we’ve already gathered incredible insights! We are eagerly looking forward to the final day of the conference, where we will wrap up with insightful discussions and key takeaways. Let’s make the most of this concluding day! #festivalofbiologics #NavigoProteins #AffinityChromatography #Ferritin #precisioncapturing #precisiontargeting #precisionmedicine #oncology #innovation #theranostics #radiopharmaceuticals

🌟 Exciting News! 🌟 Our Nexus company SPIMA Therapeutics' CEO, Mohamed Haitham Ayad, is in the spotlight with a feature in Pharmaceutical Executive! 🎤 Tune into his insightful interview linked below to learn about SPIMA's next-generation stapled peptide therapeutics, designed to tackle previously undruggable protein-protein interactions. 💡 This is a huge step forward in advancing precision medicine and revolutionizing how we address complex diseases. Don’t miss out on this game-changing conversation! 🔬✨ #SPIMATherapeutics #InnovationInBiotech #NextGenTherapeutics #PharmaceuticalExecutive #PrecisionMedicine #UndruggableTargets

Cutaneous T-cell lymphoma (CTCL) presents as a rare form of non-Hodgkin’s lymphoma, with Mycosis Fungoides (MF) representing the majority of cases at 50-60%, followed by Sezary Syndrome, accounting for 2-5% of cases. Unfortunately, advanced-stage MF patients face limited therapeutic options. Lacutamab, a pioneering anti-KIR3DL2 humanized cytotoxicity-inducing antibody currently under clinical investigation for CTCL and peripheral T cell lymphoma (PTCL). In a landscape where effective treatments are scarce, Lacutamab offers hope, showcasing impressive efficacy and outstanding tolerability in heavily treated patients. Unlock In-Depth Expert Insights and Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Reporting @ https://lnkd.in/gXZS5E_Q #asco24 #asco #asco2024 #oncoloy #CTCL #CutaneousTCellLymphoma #MycosisFungoides #SezarySyndrome #nonHodgkinsLymphoma #Lacutamab #KIR3DL2 #immunotherapy #cancerresearch #clinicaltrials #oncology #cancertreatment #PTCL #peripheralTCellLymphoma #rarelymphoma #cancerawareness #patientcare #medresearch #cancertherapy #hematology